5 results
To evaluate the long-term safety, tolerability and efficacy of ArikaceTM 590 mg for a maximum 12 cycles administered once daily, where each cycle consists of 28 days on treatment followed by 28 days off treatment.
To determine the direct effects of morning light intensity on postprandial glucose and lipid metabolism and metabolic gene expression in adipose tissue.
Primary Objective1. To evaluate the efficacy of LAI (590 mg) administered once daily (QD), when added to a multi-drug regimen, for achieving culture conversion (3 consecutive monthly negative sputum cultures) by Month 6 compared to a multi-drug…
To determine the direct effects of morning light intensity on postprandial glucose and lipid metabolism and metabolic gene expression in adipose tissue in obese subjects with and without type 2 diabetes.
Primary objectives: The first primary objective is to study the expression of PD-L1 in normal tissue and lymphoma lesions before CAR T-cell therapy in LBCL patients by 89Zr-atezolizumab PET/CT imaging and to correlate the pretreatment 89Zr-…